- Home
- ADVM vs NTRB Comparison
ADVM vs NTRB Comparison
Compare ADVM & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADVM
- NTRB
- Stock Information
- Founded
- ADVM 2006
- NTRB 2016
- Country
- ADVM United States
- NTRB United States
- Employees
- ADVM N/A
- NTRB N/A
- Industry
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- NTRB Industrial Specialties
- Sector
- ADVM Health Care
- NTRB Health Care
- Exchange
- ADVM Nasdaq
- NTRB Nasdaq
- Market Cap
- ADVM 66.3M
- NTRB 71.8M
- IPO Year
- ADVM 2014
- NTRB N/A
- Fundamental
- Price
- ADVM $3.02
- NTRB $7.00
- Analyst Decision
- ADVM Strong Buy
- NTRB Buy
- Analyst Count
- ADVM 4
- NTRB 1
- Target Price
- ADVM $19.75
- NTRB $13.00
- AVG Volume (30 Days)
- ADVM 84.1K
- NTRB 33.0K
- Earning Date
- ADVM 11-03-2025
- NTRB 09-09-2025
- Dividend Yield
- ADVM N/A
- NTRB N/A
- EPS Growth
- ADVM N/A
- NTRB N/A
- EPS
- ADVM N/A
- NTRB N/A
- Revenue
- ADVM $1,000,000.00
- NTRB $2,578,059.00
- Revenue This Year
- ADVM $1,836.70
- NTRB $560.75
- Revenue Next Year
- ADVM N/A
- NTRB $588.39
- P/E Ratio
- ADVM N/A
- NTRB N/A
- Revenue Growth
- ADVM N/A
- NTRB 42.92
- 52 Week Low
- ADVM $1.78
- NTRB $2.98
- 52 Week High
- ADVM $8.56
- NTRB $9.42
- Technical
- Relative Strength Index (RSI)
- ADVM 50.02
- NTRB 56.92
- Support Level
- ADVM $2.93
- NTRB $5.85
- Resistance Level
- ADVM $3.59
- NTRB $7.48
- Average True Range (ATR)
- ADVM 0.22
- NTRB 0.43
- MACD
- ADVM -0.02
- NTRB 0.11
- Stochastic Oscillator
- ADVM 13.64
- NTRB 71.29
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.